# Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults

> **NCT00449436** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 152 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TRIZIVIR
- **DRUG:** Non-nucleoside reverse transcriptase inhibitor
- **DRUG:** Boosted Protease Inhibitor

## Key facts

- **NCT ID:** NCT00449436
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-10
- **Primary completion:** 2007-12-12
- **Final completion:** 2007-12-13
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449436, "Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00449436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*